港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

483.155

-13.603-2.74%

漲家數：7

跌家數：23

平家數：3

市盈率：- -

高：496.758

開：496.758

低：480.328

收：496.758

成交量：1.15億

成交額：26.12億

市值：3,069.30億

流通市值：2,732.98億

資料載入中...

港股異動 | 歌禮制藥-B(01672.HK)升逾5% ASC30用於長期體重管理的全球III期臨床項目完成首例受試者給藥

歌禮制藥－Ｂ(01672)股價上升5.031%，現價港幣$10.02

阿斯达克财经

港股異動 | 再鼎醫藥(09688.HK)早盤漲近5% DLL3 ADC啓動一線SCLC全球三期臨床

港股開盤｜港股低開；醫藥股逆市走強；聯想漲逾2%

這家「最會賺錢的創新藥第一股」，貝達藥業赴港IPO，未來懸念重重……

中報之後再看心瑋醫療-B(6609.HK)：業績高增背後的神經介入邏輯

兩起涉中醫藥網絡違規營銷宣傳問題被依法查處；先聲再明與羅氏達成總金額超15億美元合作丨醫藥早參

每日经济新闻

歐康維視生物：地塞米松眼內懸濁液上市申請獲國家藥監局受理

諾華製藥（NVS）漲6% 在BTK抑制劑賽道迎來重要突破

美股異動 | 諾華製藥升逾5%，MS口服藥後期試驗告捷

諾華製藥(NVS)股票9月1日盤中上漲6.54%：真相來了

TradingKey中文

歐康維視生物-B(01477.HK)：境內生產的地塞米松眼用混懸注射液藥品註冊申請獲受理

歐康維視生物-B：國產地塞米松眼內懸濁液藥品註冊申請獲受理

歐康維視生物-B：地塞米松眼內懸濁液獲藥監局受理，列為化藥四類

匯添富基金管理股份有限公司減持康諾亞-B(02162)4.8萬股每股作價約78.40港元

歸創通橋(02190)9月1日斥資112.67萬港元回購5.3萬股

執行董事王玉曉減持榮昌生物(09995)6500股每股作價82港元

透景生命(300642.SZ)取得醫療器械註冊證

醫療器械迎業績拐點？512170成功收紅！AI4S帶火港股CXO，金斯瑞升逾7%！港股通醫療ETF華寶逆市上揚

南新制藥股民索賠案獲受理

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/BK1574/news?page=14"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":483.15506,"timestamp":1789114133774,"preClose":496.75812,"halted":0,"volume":115323363,"delay":0,"changeRate":-0.027384,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":-13.603058,"latestTime":"09-11 16:00:00","open":496.75812,"high":496.75812,"low":480.32812,"amount":2611810568,"amplitude":0.033074,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"pbRate":3.606253,"peRate":160.422718,"turnoverRate":0.004215,"increases":6,"decrements":25,"flats":1,"marketCap":306930068880,"floatMarketCap":273297591592},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":496.75812,"amplitude":0.033074,"preClose":496.75812,"low":480.32812,"pbRate":"3.606253","latestPrice":483.15506,"volume":115323363,"delay":0,"open":496.75812,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":532.025,"twentyDayClose":518.327,"sixtyDayClose":434.471,"secType":"PLATE","market":"HK","turnoverRate":0.004215,"peRate":160.422718,"marketCap":306930068880,"floatMarketCap":273297591592,"timestamp":1789114133774,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":7,"down":23,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:14,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664260860","title":"港股異動 | 歌禮制藥-B(01672.HK)升逾5% ASC30用於長期體重管理的全球III期臨床項目完成首例受試者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2664260860","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664260860?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 09:49","pubTimestamp":1788313757,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","01672","01477","BK1191","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664705860","title":"歌禮制藥－Ｂ(01672)股價上升5.031%，現價港幣$10.02","url":"https://stock-news.laohu8.com/highlight/detail?id=2664705860","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664705860?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 09:45","pubTimestamp":1788313500,"startTime":"0","endTime":"0","summary":"[上升股]歌礼制药－Ｂ(01672) 股价在上午09:45比前收市价上升5.031%，现股价为港币$10.02。至目前为止，今日最高价为$10.02，而最低价为$9.5。总成交量为25.5万股，总成交金额为港币$249.866万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180416150419953_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180416150419953_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR260902625/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR260902625/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1515","BK1191","01672","01477","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664186027","title":"港股異動 | 再鼎醫藥(09688.HK)早盤漲近5% DLL3 ADC啓動一線SCLC全球三期臨床","url":"https://stock-news.laohu8.com/highlight/detail?id=2664186027","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664186027?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 09:44","pubTimestamp":1788313443,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1588","LU2488822045.USD","BK1574","09688","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144703788","title":"港股開盤｜港股低開；醫藥股逆市走強；聯想漲逾2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1144703788","media":"港股开盘","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144703788?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 09:23","pubTimestamp":1788312190,"startTime":"0","endTime":"0","summary":"核心科网股表现分化：受AI服务器需求利好刺激，联想集团逆势上涨逾2%，其余多数龙头回调0.2%–1%不等。盘面异动方面，数据中心概念新意网高开近7%领跑；医药股获资金青睐，先声药业、云顶新耀等延续强势；黄金股则受金价走弱影响集体下挫，万物云大跌近7%拖累物业管理板块。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029875118.USD","LU0672654166.SGD","LU0128522157.USD","159938","03441","LNVGY","IE0034224299.USD","LU0572939691.SGD","LU0052756011.USD","BK1193","IE0003895053.USD","BK1574","KCAI","LU0791591158.USD","TCHI","00992","LU0049112450.USD","LU0048580855.USD","LU0572940350.SGD","LU0862451753.SGD","HK0000306701.USD","HK0000320223.HKD","BK1526","LU1235295612.USD","09939","80992","BK1515","LU1366334651.USD","BK4588","LU1366334578.USD","HK0000320264.USD","VXUS","LU0791590937.USD","LU0320764755.SGD","IE0032431581.USD","LU0310800965.SGD","LU1785774172.SGD","BK1161","BK4585","LU1046422090.SGD","LU2242644610.SGD","IE00B0JY6N72.USD","LU0128525689.USD","LU0370786039.SGD","HK0000306685.HKD","LU0543330483.HKD","LU0862451837.USD","BK1607","LU0264606111.USD","LU0972618739.USD","LU0890818403.SGD","LU1267930227.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664867024","title":"這家「最會賺錢的創新藥第一股」，貝達藥業赴港IPO，未來懸念重重……","url":"https://stock-news.laohu8.com/highlight/detail?id=2664867024","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664867024?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 08:53","pubTimestamp":1788310380,"startTime":"0","endTime":"0","summary":"老药的余晖埃克替尼之于贝达药业，是起点，也是命脉。仿制药上市后几乎必然以低价渗透市场，一旦竞争充分，埃克替尼或将被迫卷入国家或地区集中带量采购，面临进一步的降价压力。招股书承认，协议项下合计人民币1.8亿元的若干监管里程碑付款已被触发，并成为公司的应付款项。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-02/doc-iniqkvce1333036.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","REDS","KCE","BK1574","IBBQ","LNGR","IPOS","BK0060","BK1161","300558","MEDX","BK4127","159992","FRHC","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664692867","title":"中報之後再看心瑋醫療-B(6609.HK)：業績高增背後的神經介入邏輯","url":"https://stock-news.laohu8.com/highlight/detail?id=2664692867","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664692867?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 08:48","pubTimestamp":1788310086,"startTime":"0","endTime":"0","summary":"期内经调整净利润约7036.7万元，同比增幅达105.9%，远超收入增速","market":"sg","thumbnail":"https://img7.gelonghui.com/column/2/110.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/110.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6454556","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1100","06609","BK1587","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664455864","title":"兩起涉中醫藥網絡違規營銷宣傳問題被依法查處；先聲再明與羅氏達成總金額超15億美元合作丨醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2664455864","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664455864?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 07:00","pubTimestamp":1788303631,"startTime":"0","endTime":"0","summary":"丨2026年9月2日星期三丨NO.1国家中医药管理局会同有关部门依法查处两起涉中医药网络违规营销宣传问题国家中医药管理局通报称，近期，在中医医疗违法违规行为专项治理工作中，国家中医药管理局会同有关部门，依法查处了两起涉中医药网络违规营销宣传问题。一是“‘香港大药房’网店违规营销案”。多家以“香港大药房”名义开设的网店销售“透骨膏”“无湿丸”等产品，在直播营销中涉嫌虚假宣传。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023861922880.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023861922880.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1515","BK1574","159938","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198144529","title":"歐康維視生物：地塞米松眼內懸濁液上市申請獲國家藥監局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1198144529","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198144529?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 00:09","pubTimestamp":1788278991,"startTime":"0","endTime":"0","summary":"路透9月1日消息——欧康维视生物（股票代码：1477.HK）今日宣布，其地塞米松眼内悬浊液的新药上市申请，已正式获得中国国家药品监督管理局（NMPA）受理，该申请被归类为4类化学药品。此次受理标志着公司在眼科治疗领域的又一重要进展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664850928","title":"諾華製藥（NVS）漲6% 在BTK抑制劑賽道迎來重要突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2664850928","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664850928?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 23:18","pubTimestamp":1788275914,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺华制药 早盘股价扬升，最新涨6%，报161.2美元，成交额3.2亿美元。诺华周二公布，对比对照药物特立氟胺，瑞米布替尼可降低患者疾病复发率，减少脑部病灶数量，试验中未观察到肝脏相关安全风险。该药有望成为诺华重磅产品Kesimpta的后续迭代品种，同时印证BTK抑制剂在抑制异常免疫反应方面的治疗潜力。诺华计划向全球监管机构提交瑞米布替尼治疗多发性硬化症的上市申请，完整临床数据将于今年晚些时候在多伦多医学会议对外披露。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/YmFmZjgzNDhkMjgxZmE5MWVmYzk4MzgzNTg2ODExODg1NTU0MA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/YmFmZjgzNDhkMjgxZmE5MWVmYzk4MzgzNTg2ODExODg1NTU0MA==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305587","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS","BK4585","IE00BJT1NW94.SGD","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU0208291251.USD","BK4588","LU0070302665.USD","IE00BFTCPJ56.SGD","LU0320765489.SGD","BK4007","BK1191","BK1574","IE00B2B36J28.USD","BK4578","BK4532","PPH","MEDX","IE0009355771.USD","01477","LU0211331839.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664016854","title":"美股異動 | 諾華製藥升逾5%，MS口服藥後期試驗告捷","url":"https://stock-news.laohu8.com/highlight/detail?id=2664016854","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664016854?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 22:35","pubTimestamp":1788273301,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周二，诺华制药涨逾5%，报160.82美元。消息面上，诺华表示，试验显示，接受瑞米布替尼治疗的患者与接受特立氟胺治疗的患者相比，复发率和脑部病变数量均有所减少，且未观察到肝脏安全信号。该药有望为诺华提供一种治疗多发性硬化症的新型口服药物，并成为其重磅产品Kesimpta系列的后续产品。此前，赛诺菲和默克公司的类似药物在后期试验中未能在复发率指标上优于特立氟胺。","market":"fut","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490652.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"诺华制药MS口服药后期试验告捷","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","IE0009355771.USD","LU0211331839.USD","BK4532","BK4578","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0070302665.USD","NVS","LU0320765489.SGD","BK1574","PPH","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","MEDX","BK4007","BK4585","LU0208291251.USD","IE0002141913.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664524478","title":"諾華製藥(NVS)股票9月1日盤中上漲6.54%：真相來了","url":"https://stock-news.laohu8.com/highlight/detail?id=2664524478","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664524478?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 22:16","pubTimestamp":1788272176,"startTime":"0","endTime":"0","summary":"• Remibrutinib 在三期多发性硬化症试验中取得成功，展现出临床优效性。\n• 在三名患者死亡后，诺华暂停了八项早期 CAR-T 试验。\n• 该公司报告年收入为 563.3 亿美元，净利润为 139.8 亿美元。","market":"other","thumbnail":"https://resource.tradingkey.com/uploads/20251024/Novartis-369e71de347f479fa3f300f9d7904bc5.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20251024/Novartis-369e71de347f479fa3f300f9d7904bc5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262144173-market-movers-nvs-20260901","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","LU0211331839.USD","LU0208291251.USD","LU0320765489.SGD","BK4532","PPH","LU0070302665.USD","BK4588","BK1574","BK1191","BK4578","NVS","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","MEDX","IE00B4R5TH58.HKD","IE00B2B36J28.USD","IE0009355771.USD","BK4585","IE0002141913.USD","BK4007","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664856154","title":"歐康維視生物-B(01477.HK)：境內生產的地塞米松眼用混懸注射液藥品註冊申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664856154","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664856154?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 19:59","pubTimestamp":1788263997,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147045285","title":"歐康維視生物-B：國產地塞米松眼內懸濁液藥品註冊申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1147045285","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147045285?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 19:59","pubTimestamp":1788263953,"startTime":"0","endTime":"0","summary":"欧康维视生物-B近日宣布，其自主研发的地塞米松眼内悬浊液药品注册申请已正式获得受理。欧康维视生物作为一家专注于眼科领域的创新药企，持续推进其产品管线，此次申请受理是其研发进程中的重要里程碑。欧康维视生物表示，将继续与监管机构保持密切沟通，推动该产品的审评进程，并致力于加速其他在研产品的开发，以满足眼科领域未被满足的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","01477","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192737919","title":"歐康維視生物-B：地塞米松眼內懸濁液獲藥監局受理，列為化藥四類","url":"https://stock-news.laohu8.com/highlight/detail?id=1192737919","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192737919?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 19:59","pubTimestamp":1788263950,"startTime":"0","endTime":"0","summary":"欧康维视生物-B（01477.HK）宣布，其地塞米松眼内悬浊液的上市申请已获国家药品监督管理局（NMPA）正式受理。该药品被归类为化学药品第4类，这一进展标志着公司在眼科治疗领域又迈出了重要一步。此次受理的申请，不仅凸显了该产品在中国市场的监管审批进程中的关键节点，也为公司未来在该细分市场的布局增添了新的砝码。随着监管流程的推进，该药物有望为相关眼科疾病患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664856817","title":"匯添富基金管理股份有限公司減持康諾亞-B(02162)4.8萬股 每股作價約78.40港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664856817","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664856817?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 19:44","pubTimestamp":1788263089,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，8月27日，汇添富基金管理股份有限公司减持康诺亚-B(02162)4.8万股，每股作价78.4010港元，总金额约为376.32万港元。减持后最新持股数目为1489.2万股，最新持股比例为4.98%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490530.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02162","BK1583","BK1161","EWH","BK1587","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664044855","title":"歸創通橋(02190)9月1日斥資112.67萬港元回購5.3萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664044855","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664044855?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 19:43","pubTimestamp":1788263039,"startTime":"0","endTime":"0","summary":"智通财经APP讯，归创通桥(02190)发布公告，于2026年9月1日，该公司斥资112.67万港元回购5.3万股股份，每股回购价21.08-21.62港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","BK1583","02190","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664557708","title":"執行董事王玉曉減持榮昌生物(09995)6500股 每股作價82港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664557708","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664557708?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 19:35","pubTimestamp":1788262545,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，8月26日，执行董事王玉晓减持荣昌生物(09995)6500股，每股作价82港元，总金额为53.3万港元。减持后最新持股数目为2229.21万股，最新持股比例为10.69%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2328871848.SGD","LU2488822045.USD","LU2148510915.USD","LU1969619763.USD","LU1064131003.USD","BK0239","LU1064130708.USD","BK1574","BK1583","688331","EWH","09995","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664855470","title":"透景生命(300642.SZ)取得醫療器械註冊證","url":"https://stock-news.laohu8.com/highlight/detail?id=2664855470","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664855470?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 19:34","pubTimestamp":1788262475,"startTime":"0","endTime":"0","summary":"智通财经APP讯，透景生命(300642.SZ)发布公告，公司及控股子公司上海脉示生物技术有限公司于近日取得上海市药品监督管理局颁发的6项医疗器械注册证。上述医疗器械注册证的取得，丰富了公司及子公司在多个技术平台的产品线布局，进一步完善公司在非肿瘤检测领域的业务布局，有利于提升公司整体品牌影响力和市场拓展能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490557.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GDOC","HART","RSPH","09996","BK1574","300642","159883","BK1583","BK0046","LNGR","MEDX","LGHT","BK0042","MDEV","PTH","BK0239","BK1100","IEIH","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664855519","title":"醫療器械迎業績拐點？512170成功收紅！AI4S帶火港股CXO，金斯瑞升逾7%！港股通醫療ETF華寶逆市上揚","url":"https://stock-news.laohu8.com/highlight/detail?id=2664855519","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664855519?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 19:12","pubTimestamp":1788261120,"startTime":"0","endTime":"0","summary":"9月1日，A股港股医疗板块逆市表现，医疗ETF华宝、港股通医疗ETF华宝等相关品种热度再升温。医疗器械方面，英科医疗上半年营收、净利双增，迈瑞医疗利润降幅显著收窄至5.4%，联影医疗营收同比增长17%。中信建投研报指出，医疗器械行业迎来业绩修复拐点，2026Q2归母净利润实现四年首正增长，板块整体企稳回升。聚焦医疗器械+医疗服务，CXO含量超30%，兼顾脑机接口、AI医疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-01/doc-iniqipis4811448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["KCAI","159883","LNGR","BK1100","PTH","512170","BK1574","09996","BK4585","WX","MEDX","FLHK","BK4588","GDOC","IEIH","AGNG","MDEV","LGHT","HART","BK1583","VXUS","CXO","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664837323","title":"南新制藥股民索賠案獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664837323","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664837323?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 17:17","pubTimestamp":1788254220,"startTime":"0","endTime":"0","summary":"原告代理人之一、浙江裕丰律师事务所厉健律师表示，根据处罚决定，南新制药涉嫌证券虚假陈述，我们代理的部分股民索赔案已获上海金融法院正式受理。湖南证监局决定：对南新制药给予警告，并处以500万元罚款；对相关责任人员给予警告，并各处以罚款。厉健律师表示，根据司法解释，暂定：在2024年3月26日至2025年9月30日期间买入该股票，并在2025年9月30日收盘还持有南新制药股票的受损股民，可索赔。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-09-01/doc-iniqihzu4835859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":18,"pageCount":14,"totalSize":344,"code":"91000000","status":"200"}]}}